

Predicting probability of tolerating discrete amounts of peanut protein in allergic children using epitope-specific IgE antibody profiling

Maria Suprun | Paul Kearney | Clive Hayward | Heather Butler | Robert Getts | Scott H. Sicherer | Paul J. Turner
Dianne E. Campbell | Hugh A. Sampson



ARTICLE SUMMARY

- Existing diagnostic testing is not predictive of severity or the threshold dose of clinical reactivity, and many patients still require an Oral Food Challenge (OFC). While OFCs are very useful for making an allergy diagnosis and determining clinical reactivity, they often cause anaphylaxis, which can increase patient anxiety, and are time and resource intensive.¹
- An extensive validation was performed across 5 cohorts (all with confirmed oral food challenge results) across six different countries. Cohorts used: BOPI, OPIA, CAFETERIA, CoFAR6, and PEPITES with specimens from Australia, UK, US, Ireland, and Germany.
- This paper reports the first validated algorithm using two key peanut specific IgE epitopes to predict probabilities of reaction to different amounts of peanut in allergic subjects and may provide a useful clinical substitute for peanut oral food challenges.
- Using the algorithm, subjects were assigned into "high", "moderate", or "low" dose reactivity groups. On average, subjects in the "high" group were 4 times more likely to tolerate a specific dose, compared to the "low" group.¹ For example, 88% of patients in the high dose reactivity group were able to tolerate ≥ 144 mg of peanut protein whereas only 29% were able to tolerate the same amount in the low dose reactivity group.¹⁻²

CLINICAL CONSIDERATIONS

- The new epitope test offers more granular information to help clinicians stratify treatment and peanut avoidance plans for their patients.
- See below for summary of clinical considerations based on threshold reactivity level.¹

allergenis peanut diagnostic result	clinical considerations ¹
likely allergic – low dose reactor	- inform or avoid oral food challenge to reduce risk of anaphylaxis - confirm strict avoidance of peanut - consider immunotherapy to reduce risk of reaction
likely allergic – moderate dose reactor	- consider a single oral food challenge (30 to 100 mg) to reduce anxiety and improve quality of life - less stringent avoidance of peanut regime - consider inclusions of precautionary labeled foods such as 'May contain peanut' - consider immunotherapy to reduce risk of reaction
likely allergic – high dose reactor	- consider a single oral food challenge (100 to 300 mg) to reduce anxiety and improve quality of life - less stringent avoidance of peanut regime - consider inclusions of precautionary labeled foods such as 'May contain peanut' - consider starting immunotherapy at higher doses to shorten time to maintenance dose
unlikely allergic	oral food challenge to rule out the diagnosis of peanut allergy

HOW TO ORDER TESTING

- Visit allergenis.com and complete the account set up form
- Choose your phlebotomy preference (in-office or mobile phlebotomy)
- Place your order through our online platform
- Receive the results

order now

ATTEND A WEBINAR

Upcoming webinars to learn more about the clinical utility of the thresholds.

Clinical Utility of Thresholds in Patient Management

Dr. Hugh Sampson from the Icahn School of Medicine at Mount Sinai

November 21, 2022 @ 2 pm EST



Scan to register.

REFERENCES

1. Suprun M, Kearney P, Hayward C, et al. Predicting probability of tolerating discrete amounts of peanut protein in allergic children using epitope-specific IgE antibody profiling. *Allergy*. 2022;00:1-9. doi: 10.1111/all.15477

2. Sindher SB, Long A, Chin AR, Hy A, Sampath V, Nadeau KC, Chinthrajah RS. Food allergy, mechanisms, diagnosis and treatment: Innovation through a multi-targeted approach. *Allergy*. 2022 Jun 22. doi: 10.1111/all.15418. Epub ahead of print. PMID: 35730331.

Visit allergenis.com for more information or to start ordering.

Bousquet Jean (Orcid ID: 0000-0002-4061-4766)
 Vieira Rafael José (Orcid ID: 0000-0003-1834-3055)
 Amaral Rita (Orcid ID: 0000-0002-0233-830X)
 Klimek Ludger (Orcid ID: 0000-0002-2455-0192)
 Pfaar Oliver (Orcid ID: 0000-0003-4374-9639)
 Agache Ioana (Orcid ID: 0000-0001-7994-364X)
 Bergmann K-C. (Orcid ID: 0000-0002-0306-9922)
 Martins Pedro (Orcid ID: 0000-0002-4129-133X)
 Cecchi Lorenzo (Orcid ID: 0000-0002-0658-2449)
 Cingi Cemal (Orcid ID: 0000-0003-3934-5092)
 Cruz Alvaro A (Orcid ID: 0000-0002-7403-3871)
 Del Giacco Stefano R. (Orcid ID: 0000-0002-4517-1749)
 Fokkens Wytke J (Orcid ID: 0000-0003-4852-229X)
 Haahtela Tari (Orcid ID: 0000-0003-4757-2156)
 Khaitov Musa (Orcid ID: 0000-0003-4961-9640)
 Morais-Almeida Mário (Orcid ID: 0000-0003-1837-2980)
 Papadopoulos Nikolaos G (Orcid ID: 0000-0002-4448-3468)
 Patella Vincenzo (Orcid ID: 0000-0001-5640-6446)
 Rouadi philip (Orcid ID: 0000-0002-5365-9568)
 Toppila-Salmi Sanna (Orcid ID: 0000-0003-0890-6686)
 Vandenplas Olivier (Orcid ID: 0000-0002-4608-3310)
 Zuberbier Torsten (Orcid ID: 0000-0002-1466-8875)

Consistent trajectories of rhinitis control and treatment in 16,177 weeks: The MASK-air[®] longitudinal study

Short title: Longitudinal assessment of allergic rhinitis

Bernardo Sousa-Pinto¹⁻³, Holger J. Schünemann⁴, Ana Sá-Sousa¹⁻³, Rafael José Vieira¹⁻³, Rita Amaral¹⁻³, Josep M Anto⁵⁻⁸, Ludger Klimek⁹, Wienczysława Czarlewski¹⁰, Joaquim Mullol¹¹, Oliver Pfaar¹², Anna Bedbrook¹³, Luisa Brussino¹⁴, Violeta Kvedariene¹⁵, Désirée E. Larenas-Linnemann¹⁶, Yoshitaka Okamoto¹⁷, Maria Teresa Ventura¹⁸, Ioana Agache¹⁹, Ignacio J Ansotegui²⁰, Karl C Bergmann^{21,22}, Sinthia Bosnic-Anticevich²³, G Walter Canonica²⁴, Victoria Cardona²⁵, Pedro Carreiro-Martins²⁶, Thomas Casale²⁷, Lorenzo Cecchi²⁸, Tomas Chivato²⁹, Derek K Chu³⁰, Cemal Cingi³¹, Elísio M Costa³², Alvaro A Cruz³³, Stefano Del Giacco³⁴, Philippe Devillier³⁵, Patrik Eklund³⁶, Wytke J Fokkens³⁷, Bilun Gemicioglu³⁸, Tari Haahtela³⁹, Juan Carlos Ivancevich⁴⁰, Zhanat Ispayeva⁴¹, Marek Jutel⁴², Piotr Kuna⁴³, Igor Kaidashev⁴⁴, Musa Khaitov^{45,46}, Helga Kraxner⁴⁷, Daniel Laune⁴⁸, Brian Lipworth⁴⁹, Renaud Louis⁵⁰, Michael Makris⁵¹, Riccardo Monti⁵², Mario Morais-Almeida⁵³, Ralph Mösges⁵⁴, Marek Niedoszytko⁵⁵, Nikolaos G Papadopoulos⁵⁶, Vincenzo Patella⁵⁷, Nhân Pham-Thi⁵⁸, Frederico S Regateiro⁵⁹, Sietze Reitsma⁶⁰, Philip W. Rouadi⁶¹, Boleslaw Samolinski⁶², Aziz Sheikh⁶³, Milan Sova⁶⁴, Ana Todo-Bom⁶⁵, Luis Taborda-Barata⁶⁶, Sanna Toppila-Salmi³⁹, Joaquin Sastre⁶⁷, Ioanna Tsiligianni⁶⁸, Arunas Valiulis⁶⁹, Olivier Vandenplas⁷⁰, Dana Wallace⁷¹, Susan Wasserman⁷², Arzu Yorgancioglu⁷³, Mihaela Zidarn^{74,75}, Torsten Zuberbier^{21,22}, Joao A Fonseca¹⁻³, Jean Bousquet^{21,22,76}

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process which may lead to differences between this version and the [Version of Record](https://doi.org/10.1111/all.15574). Please cite this article as doi: [10.1111/all.15574](https://doi.org/10.1111/all.15574)

This article is protected by copyright. All rights reserved.

1. MEDCIDS - Department of Community Medicine, Information and Health Decision Sciences; Faculty of Medicine, University of Porto, Porto, Portugal.
2. CINTESIS – Center for Health Technology and Services Research; University of Porto, Porto, Portugal
3. RISE – Health Research Network; University of Porto, Porto, Portugal.
4. Department of Health Research Methods, Evidence, and Impact & Department of Medicine, McMaster University, Hamilton, ON, Canada.
5. ISGlobal, Barcelona Institute for Global Health, Barcelona, Spain.
6. IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain.
7. Universitat Pompeu Fabra (UPF), Barcelona, Spain.
8. CIBER Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain.
9. Department of Otolaryngology, Head and Neck Surgery, Universitätsmedizin Mainz, Mainz, and Center for Rhinology and Allergology, Wiesbaden, Germany.
10. Medical Consulting Czarlewski, Levallois, France.
11. Rhinology Unit & Smell Clinic, ENT Department, Hospital Clínic; Clinical & Experimental Respiratory Immunology, IDIBAPS, CIBERES, University of Barcelona, Spain.
12. Section of Rhinology and Allergy, Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital Marburg, Philipps-Universität Marburg, Marburg, Germany.
13. ARIA, Montpellier, France.
14. Department of Medical Sciences, Allergy and Clinical Immunology Unit, University of Torino & Mauriziano Hospital, Torino, Italy.
15. Institute of Biomedical Sciences, Department of Pathology, Faculty of Medicine, Vilnius University and Institute of Clinical medicine, Clinic of Chest diseases and Allergology, faculty of Medicine, Vilnius University, Vilnius, Lithuania.
16. Center of Excellence in Asthma and Allergy, Médica Sur Clinical Foundation and Hospital, México City, Mexico.
17. Dept of Otorhinolaryngology, Chiba University Hospital, Chiba, Japan.
18. University of Bari Medical School, Unit of Geriatric Immunology, Bari, Italy.
19. Transylvania University Brasov, Brasov, Romania.
20. Department of Allergy and Immunology, Hospital Quironsalud Bizkaia, Bilbao, Spain.
21. Institute of Allergology, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
22. Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Allergology and Immunology, Berlin, Germany.
23. Quality Use of Respiratory Medicine Group, Woolcock Institute of Medical Research, The University of Sydney, and Sydney Local Health District, Sydney, NSW, Australia.
24. Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy & Personalized Medicine, Asthma and Allergy, Humanitas Clinical and Research Center IRCCS, Rozzano, Italy.
25. Allergy Section, Department of Internal Medicine, Hospital Vall d'Hebron & ARADyAL research network, Barcelona, Spain.
26. Serviço de Imunoalergologia, Hospital de Dona Estefânia, Centro Hospitalar Universitário de Lisboa Central, Lisbon, Portugal; NOVA Medical School/Comprehensive Health Research Centre (CHRC), Lisbon, Portugal.
27. Division of Allergy/immunology, University of South Florida, Tampa, Fla, USA.
28. SOS Allergology and Clinical Immunology, USL Toscana Centro, Prato, Italy.
29. School of Medicine, University CEU San Pablo, Madrid, Spain.
30. Department of Medicine and Health Research Methods, Evidence & Impact, McMaster University, Hamilton, Ontario, Canada.
31. Eskisehir Osmangazi University, Medical Faculty, ENT Department, Eskisehir, Turkey.
32. UCIBIO, REQUINTE, Faculty of Pharmacy and Competence Center on Active and Healthy Ageing of University of Porto (Porto4Ageing), Porto, Portugal.
33. Fundação ProAR, Federal University of Bahia and GARD/WHO Planning Group, Salvador, Bahia, Brazil.
34. Department of Medical Sciences and Public Health and Unit of Allergy and Clinical Immunology, University Hospital "Duilio Casula", University of Cagliari, Cagliari, Italy.

35. VIM Suresnes, UMR_0892, Pôle des Maladies des Voies Respiratoires, Hôpital Foch, Université Paris-Saclay, Suresnes, France.
36. Umeå University, Department of Computing Science, Umeå, Sweden.
37. Department of Otorhinolaryngology, Amsterdam University Medical Centres, location AMC, Amsterdam, the Netherlands.
38. Department of Pulmonary Diseases, Istanbul University-Cerrahpasa, Cerrahpasa Faculty of Medicine, Istanbul, Turkey.
39. Skin and Allergy Hospital, Helsinki University Hospital, University of Helsinki, Finland.
40. Servicio de Alergia e Immunologia, Clinica Santa Isabel, Buenos Aires, Argentina.
41. President of Kazakhstan Association of Allergology and Clinical Immunology, Department of Allergology and clinical immunology of the Kazakh National Medical University, Almaty, Kazakhstan.
42. Department of Clinical Immunology, Wrocław Medical University, and ALL-MED Medical Research Institute, Wrocław, Poland.
43. Division of Internal Medicine, Asthma and Allergy, Barlicki University Hospital, Medical University of Lodz, Poland.
44. Poltava State Medical University, Ukraine.
45. National Research Center, Institute of Immunology, Federal Medicobiological Agency, Laboratory of Molecular immunology, Moscow, Russian Federation.
46. Pirogov Russian National Research Medical University, Moscow, Russian Federation.
47. Department of Otorhinolaryngology, Head and Neck Surgery, Semmelweis University, Budapest, Hungary.
48. KYomed INNOV, Montpellier, France.
49. Scottish Centre for Respiratory Research, Cardiovascular & Diabetes Medicine, Medical Research Institute, Ninewells Hospital, University of Dundee, UK.
50. Department of Pulmonary Medicine, CHU Sart-Tilman, and GIGA I3 research group, Liege, Belgium.
51. Allergy Unit "D Kalogeromitros", 2nd Dpt of Dermatology and Venereology, National & Kapodistrian University of Athens, "Attikon" University Hospital, Greece.
52. Department of Cardiovascular and Thoracic Sciences, Fondazione Policlinico Universitario A Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy.
53. Allergy Center, CUF Descobertas Hospital, Lisbon, Portugal.
54. IMSB, Medical Faculty, University at Cologne, and ClinCompetence Cologne GmbH, Cologne, Germany.
55. Medical University of Gdańsk, Department of Allergology, Gdansk, Poland.
56. Allergy Department, 2nd Pediatric Clinic, University of Athens, Athens, Greece.
57. Division of Allergy and Clinical Immunology, Department of Medicine, Agency of Health ASL Salerno, "Santa Maria della Speranza" Hospital, Battipaglia, Salerno, Italy.
58. Ecole Polytechnique Palaiseau, IRBA (Institut de Recherche bio-Médicale des Armées), Bretigny, France.
59. Allergy and Clinical Immunology Unit, Centro Hospitalar e Universitário de Coimbra, Coimbra and Institute of Immunology, Faculty of Medicine, University of Coimbra, and Coimbra Institute for Clinical and Biomedical Research (iCBER), Faculty of Medicine, University of Coimbra, Coimbra, Portugal.
60. Department of Otorhinolaryngology, Amsterdam University Medical Centres, AMC, Amsterdam, the Netherlands.
61. Department of Otolaryngology-Head and Neck Surgery, Eye and Ear University Hospital, Beirut, Lebanon and ENT Department, Dar Al Shifa Hospital- Salmiya, Kuwait.
62. Department of Prevention of Environmental Hazards, Allergology and Immunology, Medical University of Warsaw, Poland.
63. Usher Institute, The University of Edinburgh, Edinburgh, UK.
64. Department of Pulmonary medicine and tuberculosis, University Hospital Brno, Czech Republic.
65. Imunoalergologia, Centro Hospitalar Universitário de Coimbra and Faculty of Medicine, University of Coimbra, Portugal.
66. Faculty of Health Sciences, University of Beira Interior, Covilhã. UBIAir - Clinical & Experimental Lung Centre, University of Beira Interior, Covilhã. Department of Immunoallergology, Cova da Beira University Hospital Centre, Covilhã, Portugal.
67. Fundacion Jimenez Diaz, CIBERES, Faculty of Medicine, Autonoma University of Madrid, Spain.
68. Health Planning Unit, Department of Social Medicine, Faculty of Medicine, University of Crete, Greece and International Primary Care Respiratory Group IPCRG, Aberdeen, Scotland.

69. Institute of Clinical Medicine and Institute of Health Sciences, Medical Faculty of Vilnius University, Vilnius, Lithuania.
70. Department of Chest Medicine, Centre Hospitalier Universitaire UCL Namur, Université Catholique de Louvain, Yvoir, Belgium.
71. Nova Southeastern University, Fort Lauderdale, Florida, USA.
72. Department of Medicine, Clinical Immunology and Allergy, McMaster University, Hamilton, Ontario, Canada.
73. Celal Bayar University Department of Pulmonology, Manisa, Turkey.
74. University Clinic of Respiratory and Allergic Diseases, Golnick, Slovenia.
75. University of Ljubljana, Faculty of Medicine, Ljubljana, Slovenia
76. University Hospital Montpellier, France.

Correspondence to: Professor Jean Bousquet, Institute of Allergology, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany; Telephone: +33 611 42 88 47; Mail: jean.bousquet@orange.fr

Word count: 3497

Funding source: MASK-air® has been supported by EU grants (POLLAR, EIT Health; Structural and Development Funds, Twinning, EIP on AHA and H2020) and educational grants from Mylan-Viatris, ALK, GSK, Novartis and Uriach.

Key points

Question: What are the patterns of weekly allergic rhinitis control?

Findings: In this study assessing 113,239 days from 2,590 patients, we identified sixteen clusters of patterns of allergic rhinitis control. Clusters with poorly- or variably-controlled rhinitis displayed higher frequency of rhinitis co-medication, more frequent change of medication schemes, and more pronounced seasonal patterns.

Meaning: These results suggest that, while there are different patterns of rhinitis control, patients overall tend to treat themselves according to their symptoms rather than based on guideline recommendations.

Abstract

Introduction: Data from mHealth apps can provide valuable information on rhinitis control and treatment patterns. However, in MASK-air[®], these data have only been analyzed cross-sectionally, without considering changes of symptoms over time. We analyzed data from MASK-air[®] longitudinally, clustering weeks according to reported rhinitis symptoms.

Methods: We analyzed MASK-air[®] data, assessing weeks when patients answered a rhinitis daily questionnaire on all seven days. We firstly used k-means clustering algorithms for longitudinal data to define clusters of weeks according to the trajectories of reported daily rhinitis symptoms. Clustering was applied separately for weeks when medication was reported or not. We compared obtained clusters on symptoms and rhinitis medication patterns. We then used latent class mixture model to assess robustness of results.

Results: We analyzed 113,239 days (16,177 complete weeks) from 2,590 patients (mean age $\pm$ SD=39.1 $\pm$ 13.7 years). The first clustering algorithm identified ten clusters among weeks with medication use: seven with low variability in rhinitis control during the week, and three with highly-variable control. Clusters with poorly-controlled rhinitis displayed higher frequency of rhinitis co-medication, more frequent change of medication schemes, and more pronounced seasonal patterns. Six clusters were identified in weeks when no rhinitis medication was used, displaying similar control patterns. The second clustering method provided similar results. Moreover, patients displayed consistent levels of rhinitis control, reporting several weeks with similar levels of control.

Conclusions: We identified 16 patterns of weekly rhinitis control. Co-medication and medication change schemes were common in uncontrolled weeks, reinforcing the hypothesis that patients treat themselves according to their symptoms.

Introduction

The MASK-air® (Mobile Airways Sentinel Network for airway diseases) app is a Good Practice of DG Santé for digitally-enabled patient-centered care in rhinitis and asthma multimorbidity.^{1,2} It assesses the daily control of allergic rhinitis and asthma through visual analogue scales (VASs), which have been validated in relation to their independence,³ concurrent validity, reliability, and responsiveness.⁴ Data from MASK-air® have enabled the finding of novel phenotypes of allergic diseases,⁵ the assessment of adherence to rhinitis medications,^{6,7} and the assessment of the control associated with reported rhinitis medications.^{6,8,9} The results of MASK-air® have thus allowed the development of next-generation guidelines, incorporating real-world data.¹⁰

However, MASK-air® data were analyzed cross-sectionally, and several limitations exist for both mHealth-based studies^{6,8,9} and studies with a cross-sectional design. Cross-sectional studies cannot provide definite information about temporal relationships, let alone cause-and-effect relationships (causal inference). Such studies may also provide differing results if different timeframes are chosen, which has prompted the comparison of data during and outside the pollen season.⁹ By contrast, longitudinal studies can establish sequences of events, even though participants may drop out of the study, thereby decreasing the amount of data collected (selective attrition).^{11,12} In allergic rhinitis, a longitudinal assessment can provide information on the trajectories of patients with rhinitis (i.e., how rhinitis symptoms and medication use vary throughout certain time periods), allowing the identification of patterns of trajectories.

The aim of this study was to perform a longitudinal assessment of MASK-air® data, identifying weeks with seven days of reporting, and clustering them according to VAS levels. Clusters were then compared on rhinitis and asthma control, and on medication use, testing previous hypotheses posed in cross-sectional analyses (e.g., that days under co-medication can be associated with worse allergic rhinitis control than those under monotherapy or no medication)^{6,8,9}.

Methods

Study design

We performed a longitudinal analysis using the MASK-air® database. We identified all weeks when patients answered to the MASK-air® daily monitoring questionnaire on all seven days. To identify patterns of allergic rhinitis weeks, we applied cluster analysis methods for longitudinal data separately for weeks during which: (i) medication was used for at least one day, and (ii) medication was not used on any day. The phenotypic characteristics of the different clusters were subsequently compared.

Setting and participants

MASK-air[®] can be downloaded via the Apple App and Google Play Stores (www.mask-air.com). We included data from MASK-air[®] users (25 different countries) aged 16-90 years, with self-reported allergic rhinitis, reporting data from May 21, 2015 to December 6, 2020. In particular, we included all weeks (defined as sets of consecutive days) during which patients answered to the MASK-air[®] daily monitoring questionnaire on all days.

Ethics

MASK-air[®] has a CE1 marking. It follows the General Data Protection Regulation (GDPR).¹³ All data are anonymized using k-anonymity¹⁴. An Independent Review Board (Bohn-Köln) approval was obtained for the MASK-air studies,¹⁵ but individual boards in different countries were not required since the study is observational, and users agree to the analysis of their data in the terms of use.

Participation of the authors to the paper

B Sousa-Pinto and J Bousquet proposed the concept of the hypothesis and wrote the paper.

B Sousa-Pinto performed the analyses

HJ Schünemann, JM Anto T Zuberbier and JA Fonseca worked for the concept of the paper and the analysis of the results and reviewed the paper

A Sá-Sousa, RJ Vieira and Rita Amaral participated to the analysis of the data and reviewed the paper

L Klimek, W Czarlewski, J Mullool, O Pfaar, A Bedbrook discussed the analyses and reviewed the paper

L Brussino, V Kvedariene, DE Larenas-Linnemann, Y Okamoto, MT Ventura, KC Bergmann, S Bosnic-Anticevich, V Cardona, P Carreiro-Martins, L Cecchi, C Cingi, AA Cruz, WJ Fokkens, B Gemiciglu, JC Ivancevich, P Kuna, H Kraxner, M Makris, R Monti, M Morais-Almeida, R Mösges, M Niedozytko, NG Papadopoulos, V Patella, N Pham-Thi, FS Regateiro, S Reitsma, PW Rouadi, B Samolinski, M Sova, A Todo-Bom, L Taborda-Barata, S Toppila-Salmi, J Sastre, I Tsigianni recruited patients.

I Agache, IJ Ansotegui, GW Canonica, T Casale, T Chivato, DK Chu, EM Costa, S Del Giacco, P Devillier, PEklund, T Haahtela, Z Ispayeva, M Jutel, I Kaidashev, M Khaitov, D Laune, B Lipworth, R Louis, A Sheikh, A Valiulis, O Vandenplas and D Wallace are MASK members participating to the concept and reviewing the analyses.

All authors read the paper, most gave some comments and all agreed on its publication.

M Kaitov (Moscow) is not a member of the Russian government and participated to the paper in his own capacity

Data sources

The MASK-air[®] app comprises a daily monitoring questionnaire assessing the impact of asthma and rhinitis symptoms on a daily basis by means of 0-100 visual analogue scales (VASs). In addition, users are asked to enter their daily medications via a regularly-updated scroll list that contains country-specific prescribed and over-the-counter medications.

Size of the study

In this study, data from all complete weeks meeting inclusion criteria were included. No sample size calculation was performed.

Biases

There are potential information biases related to the self-reported nature of the data collection. Potential selection biases might occur given that app users are not representative of all rhinitis patients (e.g., there may be an overrepresentation of users suffering from moderate-to-severe rhinitis, and of younger individuals who may be more familiar with apps). Furthermore, complete weeks introduced by users in MASK-air® may not be representative of all yearly weeks.

Data analysis

Categorical variables were described by absolute and relative frequencies, while continuous variables were described by means and standard-deviations (SDs), or medians and interquartile ranges (IQRs). When responding to the MASK-air® daily monitoring questionnaire, it is not possible to skip any of the questions, and data are saved only after the final answer. This precludes any missing data.

Since selective attrition is common in MASK-air® (given that many patients use the app for a few days and/or intermittently^{6,8,9}), days from complete weeks were compared to all days of the full MASK-air® database on the characteristics of patients, VAS data, and frequency of medication use. The computation of effect sizes was based on standardized differences.

Longitudinal k-means (an adaptation of k-means clustering algorithm for longitudinal data trajectories) was applied to cluster weeks during which medication was used for at least one day. Such methods were applied to identify – in an unsupervised way and taking into account the longitudinal nature of the data – groups/patterns of weeks defined based on the VAS assessing the impact of global allergy symptoms (“VAS global”) reported during the different days of each week¹⁶ (i.e., considering their values on the different days and their variation throughout the week; no other variables were considered for clustering). A detailed description of adopted clustering methods and sensitivity analyses (along with key concepts on clustering) is included in the eMethods. Obtained clusters were then compared not only regarding VAS global values, but also regarding (i) rhinitis medication use, (ii) patients’ demographic and clinical characteristics, (iii) the ARIA-EAACI combined symptom-medication score (CSMS) assessing the daily control of allergic rhinitis, (iv) the use of asthma medication, (v) several VAS levels assessing daily allergy symptoms (including VASs on the reported impact of asthma, eye symptoms, nose symptoms, and the impact of allergy symptoms on work), and (vi) seasonality (i.e.,

distribution of the weeks of each cluster throughout the months of the year). Comparisons between clusters relied on effect sizes computed based on standardized differences. We assumed that values between 0.2 and 0.5 correspond to small effect sizes (differences), values between 0.5 and 0.8 to moderate differences and values over 0.8 to large differences.¹⁷

Similar analyses were performed for weeks during which no medication was used. Clustering was performed separately for weeks during which at least one medication was used *versus* those during which no medication was used. This helped to better explore and compare the reported severity of symptoms in weeks with and without medication use, and to characterize patients' pathways across weeks with and without medication use.

Sensitivity analyses were performed adopting a different method for clustering longitudinal data, namely the latent class mixture model (also known as “latent class growth modelling”).¹⁸ This allowed us to assess the consistency of clusters obtained in the main – non-parametric – clustering method compared to those obtained with a different – model-based – method.

Finally, we estimated, for each cluster, the risk (along with credible intervals – CrI) of a user reporting another week belonging to the same cluster or to a different cluster. This risk was estimated using Bayesian models weighted by the number of reported weeks.¹⁹

All analyses were performed using software R (version 4.0.0).

Results

Characteristics of the assessed days

We analyzed a total of 16,177 complete weeks of which 8981 (55.5%) involved the use of medication (eFigure 1). These weeks corresponded to 113,239 days of MASK-air[®] use provided by a total of 2590 users (mean age±SD=39.1±13.7 years) (Table 1; eTable 1). There were 61,299 (54.1%) days from women. Differences between assessed days and days from the full MASK-air[®] database were very small (Table 1).

Days with single medication involved, most commonly, the use of an antihistamine (14.2%), an intranasal steroid (8.4%), or azelastine-fluticasone (3.3%). Regarding co-medication schemes, intranasal steroids + antihistamines were registered in 8.6% of the days, and azelastine-fluticasone + other medication in 3.5% (Table 1).

k-means cluster analysis

Weeks when at least one medication was reported

We identified 10 clusters among weeks when at least one medication was reported (Table 2A). Three of these clusters displayed low median and maximum VAS global (named as clusters C1-C3, pointing to overall good weekly rhinitis control, with the best control being observed for C1, followed by C2 and C3), two displayed medium VAS global (clusters PC1 and PC2, indicating weekly partial rhinitis control), and two displayed high VAS global (clusters U1 and U2, suggesting weeks with poor rhinitis control). In addition, we identified three clusters with large differences between maximum, median, and minimum VAS global (clusters V1-V3, with the lowest maximum VAS being observed for V1, followed by V2 and V3) (Table 2A; Figure 1). Overall, median values of VAS nose and eyes accompanied those of median VAS global (Figure 1). For VAS asthma, this was also observed for all clusters except those with high VAS global variability (clusters V1-V3) and cluster U2. The latter appears to be associated with very poor global, nasal, and ocular control but with no/mild asthma symptoms.

Regarding rhinitis medication reporting, the percentage of days without medication varied between 11.8% (cluster U2) and 39.4% of the days (cluster V1). The frequency of co-medication days increased with severity from clusters C1 (25.5%) to U2 (65.2%). In variable clusters, it increased from 19.9% (V1) to 33.5% (V3).

Modification of treatment schemes in rhinitis medication within the same week varied from 15.9% (cluster C1) to 45.0% (cluster U2) (Figure 2). Moreover, over 10% of weeks comprised three medication schemes in clusters U1 and U2.

Regarding asthma medications, ICS-LABAs were reported from 16.3 to 22.7% of days in clusters C1 to U1. In the variable clusters (V1-V3), ICS-LABA were reported in 9.6 to 11.2% of days (eFigure 2), with the reporting of ICS-LABA increasing with VAS global level.

Weeks when no medication was reported

Six clusters were identified among weeks when no medication was reported (Table 2B). Two clusters displayed low median and maximum VAS global values (clusters NC1 and NC2), two displayed medium VAS global values (clusters NPC1 and NPC2), and one displayed high VAS global values (cluster NU). We also identified one cluster with large differences between maximum, median, and minimum VAS global values (cluster NV) (Table 2B). Median values of VAS nose and eyes increased similarly to median values of VAS global.

Sensitivity analyses

Consistent results were observed in the sensitivity analyses considering the specific weekdays when VASs were registered. For weeks when medication was reported, there was identification of three highly-variable clusters and eight (instead of seven) additional clusters (eTable 2). For weeks when no medication was reported, five clusters were identified (eTable 3).

Latent class mixture model

Using the latent class mixture model, an optimal number of eight clusters was identified for weeks when medication was used (eTable 4). The main difference between the results obtained with this approach compared to k-means lies in the identification of a single cluster with controlled rhinitis (low median and maximum VAS global) instead of three clusters. For weeks when no medication was used, the latent class mixture model also identified an optimal number of six clusters, although these encompassed a single controlled cluster (low median and maximum VAS global) and two clusters with highly variable VAS (eTable 5). The consistency of the results between the two clustering approaches was higher for weeks when medication was used than for those with no medication (eFigure 3; eTable 6).

Seasonality of clusters

Regarding clusters of weeks with reported medication use, a more pronounced seasonal pattern was observed for clusters associated with worse or more variable rhinitis control. In fact, for clusters PC2, U1-U2, and V1-V3, there was at least one spring month concentrating over 15% of observations. Clusters of untreated weeks did not show such a seasonal pattern (eFigures 4-5).

Consistency of clusters by users

For each cluster, we estimated the risk of a user reporting another week belonging to the same cluster or to a different cluster (eTable 7; Figure 3).

For a patient reporting a week with medication, there was a low risk of this patient reporting a subsequent week with no medication (8.5%; 95%CrI=6.5-10.8%). For a patient reporting a week with no medication, the risk of reporting a subsequent week with medication was of 24.3% (95%CrI=19.9-29.2%).

In clusters with reported medication use, the risk of a patient reporting a week of clusters C1-C3 in reporting another week in the same cluster ranged from 10.6% (cluster C3) to 20.8% (cluster C1). Such percentages were progressively lower for clusters PC1-PC2 (range=6.1-7.5%), U1-U2 (range=4.2-4.7%), and V1-V3 (range=1.5-2.1%) (eFigure 6). Similar observations were found for four of the clusters with no reported medication use.

Discussion

In this study, we clustered full weeks of MASK-air[®] data reporting to assess longitudinal patterns of rhinitis symptoms. We identified 16 clusters, which not only differed on VAS global patterns, but also on VASs for specific symptoms and on medication use patterns. Novel findings of this study are summarized in eBox1.

Limitations and strengths

As in any cohort study, there are several biases to be considered.²⁰ In the present study, selection biases mostly concern the fact that MASK-air[®] users may not be representative of the general population with allergic rhinitis (being younger and, potentially, more affluent and with higher access to care). Nevertheless, the impact of such selection biases may be limited. In a preliminary study, we found that data from patients aged between 65 and 74 years are similar to those of younger patients regarding symptoms and medication use patterns (Taborda-Barata et al., submitted). Symptom and medication use patterns observed in MASK-air[®] were also consistent with patterns observed from other data sources including online searches on Google Trends, antihistamine sales, and classical epidemiologic studies.²¹ On the other hand, the assessed sample appears representative of the full MASK-air[®] database, as the characteristics of the assessed days/users are similar to those of the entire database (Table 1), although the existence of unmeasured confounders (e.g., related to the severity or to the quality of/access to medical care) explaining differences in MASK-air[®] reporting patterns cannot be discarded. Observational data are also subject to information biases.²² While the tools for symptom measurement have been largely studied in MASK-air[®]^{6,8,9,23}, users may often provide incorrect information on medication use or on their profile data. Another limitation of this study concerns the impossibility of assessing the effect of medication. Even though we assessed consecutive days of data reporting, and compared medication patterns across different clusters, we were not able to assess the modifying effect of different medication classes on reported symptoms. We were not able to measure potentially-relevant variables for cluster characterization (and which could help, at least partly, to explain differences in symptoms and drug use patterns across clusters), such as patients' ease of access to the healthcare system.

This study also has important strengths. This is the first study to assess MASK-air[®] data in a longitudinal way, pointing to the possibility of assessing relevant amounts of real-world longitudinal data from patients with allergic rhinitis. Another strength concerns the fact that clusters were obtained based on VAS global, which displays high concurrent validity and reliability, as well as moderate responsiveness.²⁴ Finally, the obtained clusters may not only have face validity (as they correspond – according to a consensus of ARIA experts involved in this study – to medically relevant and recognisable week patterns) but also construct validity. The latter was assessed based on the adoption

of two different clustering methods for longitudinal data. That is, the consistency of results obtained with the two different approaches points to the validity of the clusters obtained with our main (longitudinal k-means) approach. However, we were not able to assess criterion validity due to absence of long-term outcome measures.

Interpretation of the data

In the MASK-air[®] analyses carried out so far,^{6,8,9} the unit of analysis had been the days. This implies that symptom trajectories within the same patient cannot be mapped, and that results at the day level cannot be inferred at the patient level (the same patient can provide different information on different days). Otherwise, there is a cross-level bias (from day to patient). In the present study, we moved from days to weeks. Weeks have the advantage of providing information allowing the assessment of the variability of symptoms (in VAS) within a given week. However, we cannot infer from clusters of weeks to clusters of users without incurring again in a cross-level bias, this time from week to patient. In the present study, in order to have an indication of the user diversity of weeks, we estimated the probabilities of users changing from one cluster to another. On the other hand, despite the methods adopted in this study, inferences cannot be made about the temporal relationships between treatments and symptoms. As treatments are used each day and their effect lasts for some hours, establishing such relationships would require obtaining symptom information immediately before and some hours after medication use.

We identified ten clusters based on VAS global patterns among weeks with medication use, and six clusters among weeks when no medication was used. Overall, both for weeks when medication and when no medication was used, we identified clusters which, throughout the whole week, displayed (i) good rhinitis control (low VAS global), (ii) intermediate control, (iii) poor control, and (iv) variable control. The latter, however, comprised a minority of weeks.

The study suggests a correct discrimination of clusters as shown by VAS for nose, eyes, and work as well as medications and the CSMS. Homologous clusters were observed in the “medication” and “no medication” groups, possibly pointing to the fact that control is independent of treatment.²⁵ Thirty-two (1.3%) users displayed weeks with uncontrolled rhino-conjunctivitis and controlled asthma (U2 cluster). However, such users do not seem to consistently report weeks of cluster U2, having a higher chance of reporting a subsequent week on the cluster U1 than another week on the cluster U2. Therefore, the U2 cluster may not correspond to a specific phenotype of rhinitis patients.

The identified clusters differed on medication use patterns, and the results from this study are consistent with those obtained in previous cross-sectional studies^{6,8,9}. In particular, we observed that co-medication and the use of several different medication schemes were more common in weeks of poor rhinitis

control, suggesting that (i) when patients are well-controlled, they continue their treatment without major changes, (ii) when patients are poorly controlled, they tend more often to use co-medication and/or to change their medication schemes, and (iii) patients with low adherence to their treatments tend to behave differently. These results also suggest that patients are uncertain on how to amend their medication according to their symptoms and use trial-and-error strategies rather than follow guidelines. Indication on how to step-up and step-down medication depending on symptoms and on expected pollen exposure may be a relevant future step. For this purpose, MASK-air® may play a decisive role, as it could provide alerts to users according to pollen levels, making data easily available (with the patients' consent) to their doctors.

Previous cross-sectional studies have suggested that co-medication cannot be associated with better symptom control at a population level, neither with improved control when compared to individual medications. We had compared data during and outside the pollen season and found similar results concerning monotherapy and comedication, excluding the bias of performing the study during specific time frames.⁹

In this study, weeks with medication use and with poorer or more variable rhinitis control tended to occur most often in the spring, with the remaining clusters having a less pronounced seasonal profile. This may be associated with the lack of adherence observed in cross-sectional studies,⁷ as, in this study, only around 50% of patients reported medication use. However, along with our results on cluster trajectories, this suggests that certain patients may tend to report controlled or partly-controlled weeks for most of the year, reporting occasional uncontrolled or variably-controlled weeks during the pollen season.

Cross-sectional studies cannot provide definite information on causal inference. This study is the first longitudinal study with results consistent with those from cross-sectional studies. However, future studies clustering patients reporting several full weeks of data should be performed in order to strengthen these findings.

Generalizability

Previously, only AllergyMonitor® had provided longitudinal direct patient data in rhinitis and multi-morbidities.²⁶⁻²⁸ However, there was no focus on medication use except adherence. This is, therefore, the first study using mHealth longitudinal direct patient data to assess both symptoms and treatment.

The present study was carried out in 25 countries. We could not assess individual countries due to sample size constraints. However, in previous studies, we had found consistent results when in sensitivity analyses for several outcomes in individual countries.²⁹ Thus, the results presented herein are likely to be generalizable to many developed countries.

Conclusions

Using MASK-air[®] data longitudinally, we identified 16 clusters of patterns of weekly rhinitis symptoms. The observed results were consistent with those found in previous cross-sectional studies, albeit with a more robust design. In particular, co-medication and changes in medication schemes appear to be common in weeks with higher levels of symptoms, indicating poorer rhinitis control. Such findings reinforce the hypothesis that patients treat themselves according to their symptoms rather than based on guideline recommendations. These findings suggest that guidelines proposing to increase the treatment to achieve control need to be revised in order to be centered around the patients.

Conflicts of interest:

IA reports personal fees from Roxall, Menarini, UCB, Faes Farma, Sanofi, Bial, Amgen, Abbott, Bayer, Organon.
SBA reports grants from TEVA, personal fees from TEVA, AstraZeneca, Boehringer Ingelheim, GSK, Sanofi, Mylan.
JB reports personal fees from Chiesi, Cipla, Hikma, Menarini, Mundipharma, Mylan, Novartis, Sanofi-Aventis, Takeda, Teva, Uriach, other from KYomed-Innov, personal fees from Purina, other from MASK-air.
VC reports personal fees from ThermoFisher.
PCM reports personal fees from Abbvie, AZ, Bial, GSK, Mylan, Medinfa, Novartis, Sanofi.
LC reports personal fees from Malesci, Menarini, AstraZeneca, Novartis.
AC reports grants and personal fees from Astrazeneca, GSK, Sanofi, personal fees from Boehringer-Ingelheim, Chiesi, Glenmark, Novartis, personal fees from Mylan, Abdi-Ibrahim
PD reports personal fees and non-financial support from Stallergenes Greer, ALK-Abello, AstraZeneca, CHIESI, MYLAN / Meda Pharma, Novartis, GlaxoSmithKline, Sanofi, IQVIA personal fees from MENARINI
JAFonseca reports participation in SME that has mHealth technologies for patients with asthma.
JCI reports personal fees from Abbott Ecuador, Bago Bolivia, Faes Farma, Laboratorios Casasco, Sanofi.
LK reports grants and personal fees from Allergopharma, LETI Pharma, MEDA/Mylan, Sanofi, personal fees from HAL Allergie, Allergy Therapeut., Cassella med, grants from ALK Abelló, Stallergenes, Quintiles, ASIT biotech, Lofarma, AstraZeneca, GSK, Immunotk, and Membership: AeDA, DGHNO, Deutsche Akademie für Allergologie und klinische Immunologie, HNO-BV, GPA, EAACI.
VK reports other from Noramed, Berlin Chemie Menarini.
PK reports personal fees from Adamed, AstraZeneca, Berlin Chemie Menarini, Boehringer Ingelheim, Chiesi, GSK, Novartis, Polpharma.
DLL reports personal fees from Allakos, Amstrong, Astrazeneca, Chiesi, DBV Technologies, Grunenthal, GSK, Mylan/Viatris, Menarini, MSD, Novartis, Pfizer, Sanofi, Siegfried, UCB, Alakos, Gossamer, Carnot, grants from Sanofi, Astrazeneca, Novartis, Circassia, UCB, GSK, Purina institute, Abbvie, Lilly, Pfizer.
BL reports grants and personal fees from Meda, personal fees from Glenamrk.
RL reports grants and personal fees from GSK, AZ, Chiesi, personal fees from Novartis, Sanofi.
MM reports personal fees from Novartis, Gsk, Menarini, Az, Chiesi, Sanofi, Pfizer.
RM reports personal fees from Angelini Pharma ALK, allergopharma, Allergy Therapeutics, Friulchem, Hexal, Servier, Klosterfrau, Bayer, FAES, GSK, MSD, Johnson&Johnson, Meda, Stada, UCB, Nuvo, Menarini, Mundipharma, Pohl-Boskamp, Laboratoire de la Mer, Sidroga, Lek, PRO-AdWise, grants and personal fees from Bencard, Stallergenes, Ursapharm, HAL BV, grants from Leti, Optima, BitopAG, Hulka, Immunotek, Cassella-med GmbH & Co. KG, ASIT biotech, grants, personal fees and non-financial support from Lofarma, non-financial support from Roxall, Atmos, Bionorica, Otonomy, Ferrero, personal fees and non-financial support from Novartis.
OP reports grants and personal fees from ALK-Abelló, Allergopharma, Stallergenes Greer HAL Allergy Holding B.V./HAL Allergie GmbH, Bencard Allergie GmbH/Allergy Therapeutics, Lofarma, ASIT Biotech Tools S.A., Laboratorios LETI/LETI Pharma, Anergis S.A., GlaxoSmithKline, personal fees from MEDA Pharma/MYLAN, Mobile Chamber Experts (a GA²LEN Partner), Indoor Biotechnologies, Astellas Pharma Global, EUFOREA, ROXALL Medizin, Novartis, Sanofi-Aventis and Sanofi-Genzyme, Med Update Europe GmbH, streamedup! GmbH, John Wiley and Sons, AS, Paul-Martini-Stiftung (PMS), Regeneron Pharmaceuticals Inc., RG Aerztefortbildung, Institut für Disease Management, Springer GmbH, AstraZeneca, IQVIA Commercial, Ingress Health, grants from Pohl-Boskamp, Immunotek S.L., Biomay, Circassia.
NGPapadopoulos reports personal fees from Novartis, Nutricia, HAL, MENARINI/FAESFARMA, SANOFI, MYLAN/MEDA, BIOMAY, AstraZeneca, GSK, MSD, ASIT BIOTECH, Boehringer Ingelheim, grants from Gerolymatos International SA, Capricare.
ATB reports personal fees from AstraZeneca, GSK, Novartis, IQVIA/Abbvie, Mylan, Bial, Leti, grants and personal fees from Teva.
STS reports personal fees from ERT, Roche products, Novartis, Sanofi Pharma, AstraZeneca, ALK-Abelló grants from Glaxo Smith Kline.
IT reports grants from GSK, Boehringer Ingelheim, AZ, personal fees from Novartis, AstraZeneca, Chiesi,
TZ reports Organizational affiliations: Committee member: WHO-Initiative "Allergic Rhinitis and Its Impact on Asthma" (ARIA); Member of the Board: German Society for Allergy and Clinical Immunology (DGAKI); Head: European Centre for Allergy Research Foundation (ECARF)
President: Global Allergy and Asthma European Network (GA²LEN); Member: Committee on Allergy Diagnosis and Molecular Allergology, World Allergy Organization (WAO)

References

1. Bousquet J, Bedbrook A, Czarlewski W, et al. Guidance to 2018 good practice: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma. *Clin Transl Allergy*. 2019;9:16.
2. Bousquet J, Anto JM, Bachert C, et al. From ARIA guidelines to the digital transformation of health in rhinitis and asthma multimorbidity. *Eur Respir J*. 2019;54(6).
3. Bousquet J, Bewick M, Arnavielhe S, et al. Work productivity in rhinitis using cell phones: The MASK pilot study. *Allergy*. 2017;72(10):1475-1484.
4. Sousa-Pinto B, Eklund P, O O P, et al. Validity, reliability and responsiveness of daily monitoring visual analogue scales in MASK-air®. *Clin Transl Allergy*. 2021;in press.
5. Bousquet J, Devillier P, Anto JM, et al. Daily allergic multimorbidity in rhinitis using mobile technology: A novel concept of the MASK study. *Allergy*. 2018;73(8):1622-1631.
6. Bousquet J, Devillier P, Arnavielhe S, et al. Treatment of allergic rhinitis using mobile technology with real-world data: The MASK observational pilot study. *Allergy*. 2018;73(9):1763-1774.
7. Menditto E, Costa E, Midao L, et al. Adherence to treatment in allergic rhinitis using mobile technology. The MASK Study. *Clin Exp Allergy*. 2019;49(4):442-460.
8. Bedard A, Basagana X, Anto JM, et al. Mobile technology offers novel insights into the control and treatment of allergic rhinitis: The MASK study. *J Allergy Clin Immunol*. 2019;144(1):135-143 e136.
9. Bedard A, Basagana X, Anto JM, et al. Treatment of allergic rhinitis during and outside the pollen season using mobile technology. A MASK study. *Clin Transl Allergy*. 2020;10(1):62.
10. Bousquet J, Schunemann HJ, Togias A, et al. Next-generation Allergic Rhinitis and Its Impact on Asthma (ARIA) guidelines for allergic rhinitis based on Grading of Recommendations Assessment, Development and Evaluation (GRADE) and real-world evidence. *J Allergy Clin Immunol*. 2020;145(1):70-80 e73.
11. Ibrahim JG, Molenberghs G. Missing data methods in longitudinal studies: a review. *Test (Madr)*. 2009;18(1):1-43.
12. Dong Y, Peng CY. Principled missing data methods for researchers. *Springerplus*. 2013;2(1):222.
13. Laune D, Arnavielhe S, Viart F, et al. [Adaptation of the General Data Protection Regulation (GDPR) to a smartphone app for rhinitis and asthma (MASK-air(R))]. *Rev Mal Respir*. 2019;36(9):1019-1031.
14. Samreth D, Arnavielhe S, Ingenrieth F, et al. Geolocation with respect to personal privacy for the Allergy Diary app - a MASK study. *World Allergy Organ J*. 2018;11(1):15.
15. Bousquet J, Agache I, Aliberti MR, et al. Transfer of innovation on allergic rhinitis and asthma multimorbidity in the elderly (MACVIA-ARIA) - Reference Site Twinning (EIP on AHA). *Allergy*. 2017;73(1):77-92.
16. Genolini C, Falissard B. Kml: a package to cluster longitudinal data. *Comput Methods Programs Biomed*. 2011;104(3):e112-121.
17. Cohen J. *Statistical Power Analysis for the Behavioral Sciences*. Vol <https://doi.org/10.4324/9780203771587>. New York: Taylor and Francis Group; 1988.
18. Verboon P, Hutten E, Smeekens S, Jongen E. Trajectories of loneliness across adolescence: An empirical comparison of longitudinal clustering methods using R. *J Adol* 2022;<https://doi.org/10.1002/jad.12042>.
19. Welton N, Sutton A, Cooper N, Abrams K, Ades A. *Evidence Synthesis for Decision Making in Healthcare*. John Wiley & Sons, Ltd; 2012.
20. Sedgwick P. Bias in observational study designs: prospective cohort studies. *BMJ*. 2014;349:g7731.
21. Vieira R, Sousa-Pinto B, Anto J, et al. Usage patterns of oral H1-antihistamines in 10 European countries: A study using MASK-

- air[®] and Google Trends real-world data. *World Allergy Organ J.* 2022;15:100660.
22. Hammerton G, Munafo MR. Causal inference with observational data: the need for triangulation of evidence. *Psychol Med.* 2021;51(4):563-578.
 23. Bousquet J, Anto JM, Bachert C, et al. ARIA digital anamorphosis: Digital transformation of health and care in airway diseases from research to practice. *Allergy.* 2021;76(1):168-190.
 24. Sousa-Pinto B, Eklund P, Pfaar O, et al. Validity, reliability, and responsiveness of daily monitoring visual analog scales in MASK-air(R). *Clin Transl Allergy.* 2021;11(7):e12062.
 25. Bousquet J, Anto JM, Demoly P, et al. Severe chronic allergic (and related) diseases: a uniform approach--a MeDALL--GA2LEN--ARIA position paper. *Int Arch Allergy Immunol.* 2012;158(3):216-231.
 26. Costa C, Menesatti P, Brighetti MA, et al. Pilot study on the short-term prediction of symptoms in children with hay fever monitored with e-Health technology. *Eur Ann Allergy Clin Immunol.* 2014;46(6):216-225.
 27. Di Fraia M, Tripodi S, Arasi S, et al. Adherence to Prescribed E-Diary Recording by Patients With Seasonal Allergic Rhinitis: Observational Study. *J Med Internet Res.* 2020;22(3):e16642.
 28. Giordani P, Perna S, Bianchi A, Pizzulli A, Tripodi S, Matricardi PM. A study of longitudinal mobile health data through fuzzy clustering methods for functional data: The case of allergic rhinoconjunctivitis in childhood. *PLoS One.* 2020;15(11):e0242197.
 29. Sousa-Pinto B, Filipe Azevedo L, Jutel M, et al. Development and validation of combined symptom-medication scores for allergic rhinitis. *Allergy.* 2021.

Table 1. Characteristics of the assessed sample (observations/days from complete weeks) and of observations from the full MASK-air® database

	Observations from complete weeks	Observations from the full MASK-air® database	Effect size
<i>N</i> (<i>N</i> users)	113,239 (2590)	317,176 (17,780)	-
Females – <i>N</i> (%)	61,299 (54.1)	177,067 (55.8)	0.03
Age – mean (SD)	39.1 (13.7)	38.3 (13.8)	0.06
Days from European users – <i>N</i> (%)	80,654 (71.2)	222,025 (70.0)	0.03
Asthma – <i>N</i> (%)	41,846 (37.0)	125,639 (39.6)	0.05
Conjunctivitis – <i>N</i> (%)	84,315 (74.5)	236,862 (74.7)	0.01
VAS global – median (IQR)	9 (22)	11 (27)	0.07
VAS eyes – median (IQR)	3 (13)	4 (18)	0.10
VAS nose – median (IQR)	9 (24)	12 (28)	0.10
VAS asthma – median (IQR)	0 (7)	0 (10)	0
VAS work – median (IQR)	6 (17)	8 (23)	0.10
Total days reporting rhinitis medication – <i>N</i> (%)	48,949 (43.2)	127,801 (40.3)	0.06
Antihistamines only	16,121 (14.2)	53,685 (16.9)	0.07
Intranasal steroids only	7569 (6.7)	25,380 (8.0)	0.05
Azelastine-fluticasone only	3721 (3.3)	12,745 (4.0)	0.04
Antihistamines + intranasal steroids	9786 (8.6)	25,061 (7.9)	0.03
Azelastine-fluticasone + other rhinitis medication	3997 (3.5)	9433 (3.0)	0.03
Total days reporting asthma medication – <i>N</i> (%)	18,619 (16.4)	50,492 (15.9)	0.01

IQR: Interquartile range; SD: Standard-deviation; VAS: Visual analogue scale

Table 2A. Clusters obtained when considering full weeks with at least one day of medication for allergic rhinitis

	Cluster C1	Cluster C2	Cluster C3	Cluster PC1	Cluster PC2	Cluster U1	Cluster U2	Cluster V1	Cluster V2	Cluster V3	Effect size ^a
<i>N</i> weeks (%)	2352 (26.2)	2030 (22.6)	1476 (16.4)	882 (9.8)	580 (6.5)	342 (3.8)	80 (0.9)	427 (4.8)	494 (5.5)	318 (3.5)	-
<i>N</i> days	16,464	14,210	10,332	6174	4060	2394	560	2989	3458	2226	-
<i>N</i> users (average <i>N</i> weeks per user)	534 (4.4)	692 (2.9)	559 (2.6)	405 (2.2)	285 (2.0)	210 (1.6)	32 (2.5)	325 (1.3)	390 (1.3)	270 (1.2)	-
Females – <i>N</i> (%)	1273 (54.1)	1096 (54.0)	832 (56.4)	530 (60.1)	406 (70.0)	269 (78.7)	63 (78.9)	218 (51.1)	298 (60.3)	209 (65.7)	0.6
Age – mean (SD)	39.3 (12.8)	40.0 (13.4)	39.3 (12.5)	39.6 (13.3)	39.6 (13.8)	38.0 (14.1)	46.2 (9.1)	35.7 (12.6)	35.5 (12.6)	34.4 (12.8)	1.0
VAS global allergy symptoms											
Maximum week value – median (IQR)	5 (7)	17 (9)	28 (9)	44 (12)	58 (11)	81 (17)	99 (7)	49 (17)	66 (20)	80 (22)	20.9
Minimum week value – median (IQR)	0 (1)	4 (6)	11 (7)	20 (9)	35 (13)	46 (18)	83 (22)	0 (3)	6 (9)	13 (15)	9.3
Weekly range – median (IQR)	4 (6)	12 (12)	16 (15)	24 (20)	23 (21)	36 (24)	11 (18)	48 (17)	58 (20)	67 (25)	4.9
Median week value – median (IQR)	0 (4)	9 (4)	18 (5)	30 (7)	47 (9)	62 (11)	91 (11)	7 (10)	20 (9)	43 (15)	19.3
Days with VAS >50 – <i>N</i> (%)	0	0	1 (0.01)	244 (4.0)	1501 (37.0)	1931 (80.7)	559 (99.8)	196 (6.6)	576 (16.7)	911 (40.9)	3.1
Rhinitis medication reporting – <i>N</i> (%)											
No medication days	3623 (22.0)	3249 (22.9)	2166 (21.0)	956 (15.5)	604 (14.9)	416 (17.4)	66 (11.8)	1178 (39.4)	1120 (32.4)	540 (24.3)	0.7
Single medication days	8636 (52.5)	6782 (47.7)	4950 (47.9)	2628 (42.6)	1787 (44.0)	904 (37.8)	129 (23.0)	1215 (40.6)	1462 (42.3)	941 (42.3)	0.6
Co-medication days	4205 (25.5)	4179 (29.4)	3216 (31.1)	2590 (42.0)	1669 (41.1)	1074 (44.9)	365 (65.2)	596 (19.9)	876 (25.3)	745 (33.5)	1.0
Total days reporting AR medication – <i>N</i> (%)											
Only AH	4163 (25.3)	3464 (24.4)	2606 (25.2)	1564 (25.3)	1126 (27.7)	510 (21.3)	63 (11.3)	793 (26.5)	1137 (32.9)	695 (31.2)	0.5
Single AH use	4099 (24.9)	3305 (23.3)	2452 (23.7)	1437 (23.3)	998 (24.6)	420 (17.5)	39 (7.0)	748 (25.0)	1004 (29.0)	651 (29.2)	0.6
Several AH use	64 (0.4)	159 (1.1)	154 (1.5)	127 (2.1)	128 (3.2)	90 (3.8)	24 (4.3)	45 (1.5)	133 (3.8)	44 (2.0)	0.3
Only INCS	2736 (16.6)	1918 (13.5)	1235 (12.0)	513 (8.3)	277 (6.8)	198 (8.3)	72 (12.9)	235 (7.9)	262 (7.6)	123 (5.5)	0.4
Only AzeFlu	1343 (8.2)	863 (6.1)	667 (6.5)	257 (4.2)	182 (4.5)	159 (6.6)	0	99 (3.3)	92 (2.7)	59 (2.7)	0.6
AH + INCS	2111 (12.8)	1482 (10.4)	835 (8.1)	684 (11.1)	478 (11.8)	321 (13.4)	109 (19.5)	276 (9.2)	312 (9.0)	266 (11.9)	0.3
AH + INCS + others	259 (1.6)	832 (5.9)	660 (6.4)	397 (6.4)	228 (5.6)	170 (7.1)	48 (8.6)	54 (1.8)	117 (3.4)	147 (6.6)	0.3
AzeFlu + others	777 (4.7)	884 (6.2)	775 (7.5)	715 (11.6)	271 (6.7)	244 (10.2)	41 (7.3)	102 (3.4)	100 (2.9)	88 (4.0)	0.4
OCS	63 (0.4)	126 (0.9)	68 (0.7)	228 (3.7)	209 (5.1)	116 (4.8)	26 (4.6)	6 (0.2)	38 (1.1)	35 (1.6)	0.4
<i>N</i> medication schemes per week (%)											
One scheme	1979 (84.1)	1509 (74.3)	1034 (70.1)	618 (70.1)	422 (72.8)	219 (64.0)	44 (55.0)	324 (75.9)	357 (72.3)	222 (69.8)	0.7
Two different schemes	336 (14.3)	442 (21.8)	381 (25.8)	221 (25.1)	127 (21.9)	86 (25.1)	24 (30.0)	89 (20.8)	112 (22.7)	76 (23.9)	0.4
Three or more different schemes	37 (1.6)	79 (3.9)	61 (4.1)	43 (4.9)	31 (5.3)	37 (10.8)	12 (15.0)	14 (3.3)	25 (5.1)	20 (6.3)	0.5
<i>N</i> weeks according to the number of medication use days (%)											
1 day of medication use	246 (10.5)	196 (9.7)	120 (8.1)	36 (4.1)	26 (4.5)	20 (5.8)	3 (3.8)	97 (22.7)	73 (14.8)	22 (6.9)	0.6
2 days of medication use	128 (5.4)	123 (6.1)	87 (5.9)	36 (4.1)	25 (4.3)	11 (3.2)	1 (1.3)	56 (13.1)	43 (8.7)	19 (6.0)	0.5

3 days of medication use	115 (4.9)	117 (5.8)	70 (4.7)	42 (4.8)	23 (4.0)	15 (4.4)	2 (2.5)	30 (7.0)	43 (8.7)	22 (6.9)	0.3
4 days of medication use	127 (5.4)	120 (5.9)	77 (5.2)	41 (4.6)	25 (4.3)	16 (4.7)	1 (1.3)	25 (5.9)	39 (7.9)	33 (10.4)	0.4
5 days of medication use	173 (7.4)	156 (7.7)	133 (9.0)	67 (7.6)	35 (6.0)	33 (9.6)	5 (6.3)	28 (6.6)	52 (10.5)	35 (11.0)	0.2
6 days of medication use	320 (13.6)	318 (15.7)	234 (15.9)	135 (15.3)	86 (14.8)	67 (19.6)	22 (27.5)	65 (15.2)	74 (15.0)	56 (17.6)	0.4
7 days of medication use	1243 (52.8)	1000 (49.3)	755 (51.2)	525 (59.5)	360 (62.1)	180 (52.6)	46 (57.5)	126 (29.5)	170 (34.4)	131 (41.2)	0.7
Combined symptom-medication score											
Maximum weekly value – median (IQR)	6.5 (5.7)	14.0 (7.3)	21.0 (8.9)	31.9 (13.3)	43.6 (15.1)	56.4 (19.7)	73.2 (18.5)	32.2 (16.7)	42.0 (19.4)	55.4 (19.6)	4.7
Median weekly value – median (IQR)	3.7 (3.9)	8.6 (5.5)	14.6 (7.0)	23.1 (9.6)	35.0 (14.7)	44.1 (15.9)	69.5 (13.9)	6.7 (7.0)	14.7 (10.1)	29.7 (15.0)	4.7
Weeks during the pollen season – <i>N</i> (%) ^b	348 (20.2)	443 (26.9)	310 (27.1)	170 (27.2)	133 (30.2)	75 (27.1)	8 (22.2)	94 (29.8)	122 (34.3)	76 (32.6)	0.3
Maximum weekly VAS eyes – median (IQR)	3 (7)	11 (14)	20 (22)	34 (31)	51 (32)	71 (47)	95 (14)	27 (45)	43 (45)	69 (38)	14.0
Median weekly VAS eyes – median (IQR)	0 (3)	4 (8)	9 (15)	19 (25)	35 (37)	42 (51)	85 (25)	1 (7)	9 (20)	25 (36)	7.7
Maximum weekly VAS nose – median (IQR)	6 (10)	18 (13)	30 (14)	46 (18)	60 (15)	82 (21)	99 (9)	50 (28)	66 (28)	81 (27)	17.0
Median weekly VAS nose – median (IQR)	2 (5)	9 (7)	19 (8)	31 (10)	48 (13)	62 (19)	91 (15)	7 (12)	20 (16)	43 (24)	13.4
Maximum weekly VAS work – median (IQR)	3 (6)	11 (10)	21 (14)	36 (18)	50 (19)	65 (20)	89 (22)	21 (31)	42 (34)	55 (33)	12.2
Median weekly VAS work – median (IQR)	0 (3)	7 (8)	14 (12)	27 (15)	39 (22)	52 (18)	83 (26)	4 (10)	16 (18)	32 (25)	8.3
Baseline <i>N</i> AR symptoms – mean (SD)	4.5 (2.1)	4.7 (1.9)	5.0 (1.7)	4.9 (1.7)	4.7 (1.9)	4.9 (1.9)	4.8 (1.4)	4.8 (1.9)	5.0 (1.8)	5.1 (1.8)	0.3
Baseline <i>N</i> domains of AR impact – mean (SD)	1.8 (1.5)	1.9 (1.4)	2.1 (1.4)	2.1 (1.4)	2.0 (1.5)	2.1 (1.5)	2.2 (1.2)	1.9 (1.4)	2.0 (1.4)	2.0 (1.3)	0.3
Conjunctivitis – <i>N</i> (%)	1643 (69.9)	1534 (75.6)	1180 (79.9)	717 (81.3)	431 (74.3)	259 (75.7)	65 (81.3)	324 (75.9)	401 (81.2)	269 (84.6)	0.4
Self-reported asthma – <i>N</i> (%)	921 (39.2)	864 (42.6)	590 (40.0)	357 (40.5)	253 (43.6)	155 (45.3)	27 (33.8)	150 (35.1)	167 (33.8)	112 (35.2)	0.2
VAS asthma											
Maximum value – median (IQR)	1 (6)	6 (15)	6 (23)	11 (40)	28 (55)	51 (75)	60 (87)	5 (31)	9 (46)	18 (67)	1.4
Minimum week value – median (IQR)	0 (0)	0 (4)	0 (7)	0 (15)	5 (35)	9 (47)	3 (56)	0 (0)	0 (3)	0 (8)	1.0
Weekly range – median (IQR)	1 (5)	4 (10)	4 (15)	9 (23)	9 (25)	21 (38)	9 (33)	4 (27)	8 (41)	15 (53)	1.1
Median week value – median (IQR)	0 (3)	0 (8)	1 (13)	4 (26)	14 (46)	26 (63)	7 (77)	0 (4)	0 (12)	2 (26)	1.0
Total days reporting asthma medication – <i>N</i> (%)											
SABA	192 (1.2)	291 (2.0)	314 (3.0)	257 (4.2)	394 (9.7)	358 (15.0)	51 (9.1)	64 (2.1)	98 (2.8)	91 (4.1)	0.6
LABA/LABA+ICS	2687 (16.3)	2872 (20.2)	1777 (17.2)	1050 (17.0)	920 (22.7)	530 (22.1)	48 (8.6)	286 (9.6)	354 (10.2)	249 (11.2)	0.4
ICS	846 (5.1)	539 (3.8)	549 (5.3)	318 (5.2)	257 (6.3)	143 (6.0)	26 (4.6)	97 (3.2)	110 (3.2)	72 (3.2)	0.1
Other	88 (0.5)	121 (0.9)	124 (1.2)	242 (3.9)	86 (2.1)	39 (1.6)	11 (2.0)	7 (0.2)	29 (0.8)	28 (1.3)	0.3

AH Antihistamines; AR: Allergic rhinitis; AzeFlu: Azelastine-fluticasone; ICS: Inhaled corticosteroids; INCS: Intranasal corticosteroids; IQR: Interquartile range; LABA: Long-acting beta-agonist; OCS: Oral corticosteroids; SABA: Short-acting beta-agonist; SD: Standard-deviation; VAS: Visual Analogue Scale; ^a Effect size for the largest difference between clusters. All comparisons have a *p*-value<0.001 using classical inferential hypothesis tests (chi-square test for categorical variables and Kruskal-Wallis test for continuous variables). In linear discriminant analysis, the first linear discriminant function achieved a proportion of trace (percentage of separation) of 91.3%. A linear discriminant analysis model based on daily VASs in a training dataset (80% of the assessed sample) was able to correctly predict the cluster for 95.4% of the weeks in a test dataset; ^b Considering only the weeks reported by European patients, and whose total value is of 1724 for cluster A, 1644 for cluster B, 1143 for cluster C, 626 for cluster D, 441 for cluster E, 356 for cluster F, 315 for cluster G, 277 for cluster H, 233 for cluster I, 36 for cluster J.

Table 2B. Clusters obtained when considering full weeks with no medication for allergic rhinitis

	Cluster NC1	Cluster NC2	Cluster NPC1	Cluster NPC2	Cluster NU	Cluster NV	Effect size ^a
<i>N</i> weeks (%)	3623 (50.3)	1777 (24.7)	824 (11.5)	466 (6.5)	175 (2.4)	331 (4.6)	-
<i>N</i> days	25,361	12,439	5768	3262	1225	2317	-
<i>N</i> users (average <i>N</i> weeks per user)	556 (6.5)	538 (3.3)	291 (2.8)	206 (2.3)	100 (1.8)	234 (1.4)	-
Females – <i>N</i> (%)	1602 (44.2)	869 (48.9)	448 (54.4)	332 (71.2)	116 (66.3)	196 (59.2)	0.6
Age – mean (SD)	38.9 (13.9)	40.0 (14.8)	42.3 (15.8)	39.2 (14.4)	39.4 (15.1)	32.6 (11.9)	0.7
VAS global allergy symptoms							
Maximum week value – median (IQR)	1 (6)	18 (10)	31 (11)	55 (16)	78 (23)	61 (20)	6.7
Minimum week value – median (IQR)	0 (0)	5 (7)	15 (8)	27 (16)	50 (19)	3 (7)	5.3
Weekly range – median (IQR)	1 (5)	12 (12)	15 (14)	27 (29)	28 (34)	55 (22)	5.1
Median week value – median (IQR)	0 (1)	9 (5)	21 (7)	42 (12)	62 (12)	16 (14)	11.8
Days with VAS > 50 – <i>N</i> (%)	0	13 (0.1)	14 (0.2)	744 (22.8)	1032 (84.2)	323 (13.9)	2.3
Combined symptom-medication score							
Maximum weekly value – median (IQR)	1.8 (4.5)	11.6 (7.1)	20.5 (8.8)	40.5 (16.5)	54.8 (19.0)	35.6 (17.6)	5.2
Median weekly value – median (IQR)	0 (1.9)	6.8 (4.7)	15.1 (6.9)	30.0 (15.3)	43.6 (17.6)	10.9 (9.8)	4.9
Weeks during the pollen season – <i>N</i> (%) ^b	278 (10.7)	193 (18.0)	92 (19.9)	68 (26.1)	31 (27.9)	58 (26.2)	0.5
Maximum weekly VASeyes – median (IQR)	0 (4)	11 (15)	24 (18)	50 (31)	69 (35)	36 (47)	3.9
Median weekly VASeyes – median (IQR)	0 (0)	5 (9)	16 (16)	34 (35)	52 (47)	5 (14)	2.8
Maximum weekly VASnose – median (IQR)	2 (7)	19 (14)	33 (15)	56 (22)	80 (24)	63 (27)	6.7
Median weekly VAS nose – median (IQR)	0 (2)	10 (7)	22 (9)	44 (14)	64 (16)	17 (21)	8.7
Maximum weekly VASwork – median (IQR)	0 (4)	12 (10)	26 (16)	48 (18)	67 (18)	35 (31)	7.1
Median weekly VAS work – median (IQR)	0 (1)	8 (8)	18 (13)	38 (19)	57 (16)	12 (16)	6.8
Baseline <i>N</i> AR symptoms – mean (SD)	4.5 (1.9)	4.6 (1.9)	5.0 (1.8)	4.8 (2.3)	4.8 (2.1)	4.9 (1.9)	0.3
Baseline <i>N</i> domains of AR impact – mean (SD)	1.9 (1.4)	1.7 (1.3)	1.9 (1.3)	1.9 (1.4)	2.3 (1.4)	1.8 (1.5)	0.4
Conjunctivitis – <i>N</i> (%)	2451 (67.7)	1318 (74.2)	710 (86.2)	346 (74.2)	138 (78.9)	259 (78.2)	0.5
Self-reported asthma – <i>N</i> (%)	1300 (35.9)	601 (33.8)	199 (24.2)	129 (27.7)	48 (27.4)	105 (31.7)	0.3
VAS asthma							
Maximum value – median (IQR)	0 (3)	5 (15)	3 (25)	26 (53)	12 (72)	5 (40)	0.9
Minimum week value – median (IQR)	0 (0)	0 (5)	0 (10)	4 (28)	1 (38)	0 (2)	1.0
Weekly range – median (IQR)	0 (3)	4 (10)	3 (14)	10 (26)	8 (25)	5 (35)	0.7
Median week value – median (IQR)	0 (0)	0 (9)	0 (18)	13 (42)	5 (57)	0 (8)	1.0
Total days reporting asthma medication – <i>N</i> (%)							
SABA	176 (0.7)	112 (0.9)	31 (0.5)	60 (1.8)	9 (0.7)	37 (1.6)	0.1
LABA/LABA+ICS	1158 (4.6)	1057 (8.5)	365 (6.3)	99 (3.0)	25 (2.0)	108 (4.7)	0.3
ICS	715 (2.8)	573 (4.6)	81 (1.4)	10 (0.3)	7 (0.6)	30 (1.3)	0.3
Other	30 (0.1)	94 (0.8)	6 (0.1)	0	0	2 (0.1)	0.2

AR: Allergic rhinitis; ICS: Inhaled corticosteroids; IQR: Interquartile range; LABA: Long-acting beta-agonist; SABA: Short-acting beta-agonist; SD: Standard-deviation; VAS: Visual Analogue Scale; ^a Effect size for the largest difference between clusters. All comparisons have a *p*-value < 0.001 using classical inferential hypothesis tests (chi-square test for categorical variables and Kruskal-Wallis test for continuous variables). In linear discriminant analysis, the first linear discriminant function achieved a proportion of trace (percentage of separation) of 94.2%. A linear discriminant analysis model based on daily VASs in a training dataset (80% of the assessed sample) was able to correctly predict the cluster for 94.1% of the weeks in a test dataset; ^b Considering only the weeks reported by European patients, and whose total value is of 2600 for cluster AA, 1071 for cluster BB, 463 for cluster CC, 261 for cluster DD, 221 for cluster EE, and 111 for cluster FF.

Figure 1: Variation of median VAS global levels (A) and median VAS global, nose, eye and asthma levels (B) in the different clusters




Figure 2: Percentage of days under rhinitis medication (A), and percentage of different weekly rhinitis medication schemes (B) for the 10 clusters reporting at least one medication day per week




Figure 3. Risks of a user reporting another week belonging to the same cluster or to a different cluster. The thickness of the arrows is proportional to the risk. Risks below 2% are not plotted.

